Shares of Mineralys Therapeutics Inc. (MLYS) are up nearly 40% at $21 in premarket trading, following AstraZeneca's (AZN) positive trial results for Baxdrostat, a highly selective aldosterone synthase inhibitor, or ASI, for hypertension. As Mineralys is also developing ASIs targeting hypertension and related cardiorenal conditions, the news has triggered a domino effect, lifting sentiment across the ASI space.
Mineralys' lead drug candidate is Lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled hypertension (uHTN) & resistant hypertension (rHTN), chronic kidney disease, and obstructive sleep apnea.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.